^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

UBE3A (Ubiquitin Protein Ligase E3A)

i
Other names: UBE3A, Ubiquitin Protein Ligase E3A, EPVE6AP, HPVE6A, E6-AP, ANCR, AS, Human Papilloma Virus E6-Associated Protein, Human Papillomavirus E6-Associated Protein, Oncogenic Protein-Associated Protein E6-AP, HECT-Type Ubiquitin Transferase E3A, Renal Carcinoma Antigen NY-REN-54, E6AP Ubiquitin-Protein Ligase, Ubiquitin-Protein Ligase E3A, FLJ26981, CTCL Tumor Antigen Se37-2, Angelman Syndrome, E6AP
12d
Destabilization of lipoma-preferred partner by TGF-β-induced O-GlcNAcylation promotes hepatocellular carcinoma metastasis. (PubMed, Biochim Biophys Acta Mol Cell Res)
Conversely, LPP depletion accelerates metastatic outgrowth and associates with reduced patient survival. Collectively, our findings reveal a TGF-β/GFAT1/LPP axis that couples metabolic reprogramming to metastatic competence, and highlight O-GlcNAcylation blockade or targeted stabilization of LPP as potential therapeutic strategies against metastatic HCC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • UBE3A (Ubiquitin Protein Ligase E3A)
2ms
Brusatol Exerts Therapeutic Effects in Ulcerative Colitis by Regulating the UBE3A-LCN2-Mediated Ferroptosis and Inflammation Axis. (PubMed, Chem Biol Drug Des)
In the UC mouse model, BR mitigated colonic pathological damage, downregulated LCN2 expression, and upregulated UBE3A levels. BR exerted anti-colitis effects by upregulating the expression of UBE3A and downregulating LCN2 levels, thereby inhibiting cell injury, ferroptosis, and colonic pathological damage.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • LCN2 (Lipocalin-2) • UBE3A (Ubiquitin Protein Ligase E3A)
2ms
Trial completion
|
UBE3A (Ubiquitin Protein Ligase E3A)
2ms
Dysfunction of the Autophagy System and MDM2-p53 Axis Leads to the Accumulation of Amyloidogenic Proteins in Angelman Syndrome Models. (PubMed, Int J Mol Sci)
Nevertheless, UB3A- cells do not show evident morphological abnormalities. Overall, these data suggest that AS models presented an altered signaling pathway related to autophagy/UPS systems, potentially leading to the accumulation of toxic proteins affecting synaptic development.
Journal
|
TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • UBE3A (Ubiquitin Protein Ligase E3A)
3ms
Angelman Syndrome With Papillary Urothelial Carcinoma: An Unusual Initial Presentation and Two Recurrences. (PubMed, Cureus)
Angelman syndrome is a rare neurodevelopmental disorder caused by a defect in the UBE3A gene, leading to characteristic neurological and behavioral manifestations. Although no clear association exists between these two conditions, we report a case of a 36-year-old man with Angelman syndrome who developed urothelial carcinoma of the urinary bladder despite the absence of identifiable risk factors or a family history of urothelial cancer, followed by two subsequent recurrences.
Journal
|
UBE3A (Ubiquitin Protein Ligase E3A)
3ms
PRDX1 Suppresses Oxidative Stress and Senescence in HUVECs by Stabilizing TRAF4. (PubMed, J Histochem Cytochem)
The promotion of PRDX1 on proliferation, migration, and angiogenesis was canceled by knockdown of TRAF4. PRDX1 inhibited oxidative stress and senescence via restraining the degradation of TRAF4 by binding to UBE3A, eventually accelerating wound healing.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • PRDX1 (Peroxiredoxin 1) • UBE3A (Ubiquitin Protein Ligase E3A)
5ms
Enrollment open • Enrollment change
|
UBE3A (Ubiquitin Protein Ligase E3A)
5ms
Covalent Inhibition of the Human Papillomavirus Type 16 E6 Protein Restores p53 and Suppresses HPV-Driven Tumorigenesis. (PubMed, bioRxiv)
In vivo , E6 inhibition suppresses the growth of human HPV16 expressing cervical and oropharyngeal tumor cell lines in mice. The strategy of targeting a viral oncoprotein with a covalent inhibitor demonstrates a genotype-specific therapeutic strategy for HPV-associated cancers and premalignant infections, addressing a significant unmet need in current treatment options.
Journal
|
UBE3A (Ubiquitin Protein Ligase E3A)
6ms
Trial completion
|
UBE3A (Ubiquitin Protein Ligase E3A)
6ms
Investigating the therapeutic efficacy of all-trans retinoic acid in autism spectrum disorder patients with 15q11-13 duplication syndrome (ChiCTR2500106809)
P=N/A, N=90, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
New trial
|
UBE3A (Ubiquitin Protein Ligase E3A)
6ms
Enrollment closed
|
UBE3A (Ubiquitin Protein Ligase E3A)
10ms
Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism. (PubMed, Elife)
In breast cancer patients, FRMD8 gene promoter is found hypermethylated and low level of FRMD8 predicts poor prognosis. Therefore, FRMD8 is an important regulator of ERα and may control therapeutic sensitivity to tamoxifen in ERα-positive breast cancer patients.
Journal
|
ER (Estrogen receptor) • FOXO3 (Forkhead box O3) • UBE3A (Ubiquitin Protein Ligase E3A)
|
ER positive
|
tamoxifen